Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Hodgkin Disease 36Lymphoma 34Lymphoma, Non-Hodgkin 24Lymphoma, Large B-Cell, Diffuse 24Lymphoma, Follicular 18Lymphoma, B-Cell 16Recurrence 15Melanoma 14Neoplasms 12Mycosis Fungoides 9Lymphoma, T-Cell 9Breast Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, T-Cell, Cutaneous 7Lymphoma, B-Cell, Marginal Zone 7Head and Neck Neoplasms 7Sezary Syndrome 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Mantle-Cell 6Lung Neoplasms 6Carcinoma, Renal Cell 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasm Metastasis 5Lymphoma, T-Cell, Peripheral 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Follicular × pembrolizumab × Lymphoid × Clear all
NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡